Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.34 |
| ▸ | CRHBP | P24387 | 1/20 | 0.34 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.34 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.34 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.34 |
| ▸ | TEK | Q02763 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6177655 | 1.00 | LTA4H (0.35) | LTA4HGPR55MEN1KMT2AALDH1A1 | |
| SCHEMBL6180626 | 0.87 | USP2 (0.34) | LTA4HGPR55MEN1KMT2AALDH1A1 | |
| SCHEMBL6178031 | 0.85 | ALDH1A1 (0.39) | MEN1KMT2AALDH1A1MAPTUSP2 | |
| SCHEMBL6178028 | 0.85 | ALDH1A1 (0.39) | MEN1KMT2AALDH1A1MAPTUSP2 | |
| SCHEMBL6175600 | 0.84 | USP2 (0.34) | MEN1KMT2AUSP2SORT1 | |
| SCHEMBL6175596 | 0.84 | USP2 (0.34) | MEN1KMT2AUSP2SORT1 | |
| SCHEMBL6176914 | 0.83 | ALDH1A1 (0.37) | MEN1KMT2AALDH1A1MAPTUSP2 | |
| SCHEMBL6177463 | 0.83 | SMN1; SMN2 (0.36) | ALDH1A1USP2TEKSMN1; SMN2 | |
| SCHEMBL4001548 | 0.80 | MMP9 (0.36) | MEN1KMT2ASMN1; SMN2SORT1 | |
| SCHEMBL4003199 | 0.80 | MMP9 (0.36) | MEN1KMT2ASMN1; SMN2SORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050176966-A1 | Process for the preparation of pyrimidine derivative, intermediate therefor and process for the preparation thereof | AJINOMOTO CO., INC. (JP) | 2005-08-11 | — | — | US | disclosed |
| EP-1529778-A1 | Production method of pyrimidine derivative, intermediate therefor | Ajinomoto Co., Inc. (JP) | 2005-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176966-A1 | Process for the preparation of pyrimidine derivative, intermediate therefor and process for the preparation thereof | DPYD, WEE1, DCXR | LTA4H 1177/4885GPR55 3985/4885MEN1 1538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.